lunes, 24 de abril de 2017

Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurren... - PubMed - NCBI

Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurren... - PubMed - NCBI



 2017 Apr 13;17(1):265. doi: 10.1186/s12885-017-3261-1.

Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10).

Pestalozzi BC1, Tausch C2, Dedes KJ3, Rochlitz C4, Zimmermann S5, von Moos R6, Winterhalder R7, Ruhstaller T8, Mueller A9, Buser K10, Borner M11, Novak U12, Nussbaum CU13, Seifert B14, Bigler M15, Bize V15, Vilei SB15, Rageth C2, Aebi S7; Swiss Group for Clinical Cancer Research (SAKK).

Abstract

BACKGROUND:

To evaluate the effect of Recurrence Score® results (RS; Oncotype DX® multigene assay ODX) on treatment recommendations by Swiss multidisciplinary tumor boards (TB).

METHODS:

SAKK 26/10 is a multicenter, prospective cohort study of early breast cancer patients: Eligibility: R0-resection, ≥10% ER+ malignant cells, HER2-, pN0/pN1a. Patients were stratified into low-risk (LR) and non-low-risk (NLR) groups based on involved nodes (0 vs 1-3) and five additional predefined risk factors. Recommendations were classified as hormonal therapy (HT) or chemotherapy plus HT (CT + HT). Investigators were blinded to the statistical analysis plan. A 5%/10% rate of recommendation change in LR/NLR groups, respectively, was assumed independently of RS (null hypotheses).

RESULTS:

Two hundred twenty two evaluable patients from 18 centers had TB recommendations before and after consideration of the RS result. A recommendation change occurred in 45 patients (23/154 (15%, 95% CI 10-22%) in the LR group and 22/68 (32%, 95% CI 22-45%) in the NLR group). In both groups the null hypothesis could be rejected (both p < 0.001). Specifically, in the LR group, only 5/113 (4%, 95% CI 1-10%) with HT had a recommendation change to CT + HT after consideration of the RS, while 18/41 (44%, 95% CI 28-60%) of patients initially recommended CT + HT were subsequently recommended only HT. In the NLR group, 3/19 (16%, 95% CI 3-40%) patients were changed from HT to CT + HT, while 19/48 (40%, 95% CI 26-55%) were changed from CT + HT to HT.

CONCLUSION:

There was a significant impact of using the RS in the LR and the NLR group but only 4% of LR patients initially considered for HT had a recommendation change (RC); therefore these patients could forgo ODX testing. A RC was more likely for NLR patients considered for HT. Patients considered for HT + CT have the highest likelihood of a RC based on RS.

KEYWORDS:

Adjuvant treatment recommendation; ER-positive early breast cancer; Multigene expression profiling; Oncotype DX; Recurrence score

PMID:
 
28407750
 
PMCID:
 
PMC5390385
 
DOI:
 
10.1186/s12885-017-3261-1
Free PMC Article





Last Posted: Apr 20, 2017

Publicado por en

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)